Navigation Links
Roka Bioscience Announces Pricing of Initial Public Offering
Date:7/17/2014

WARREN, N.J., July 17, 2014 /PRNewswire/ -- Roka Bioscience, Inc., a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $12.00 per share, before underwriting discounts.  All of the common stock is being offered by Roka Bioscience.  In addition, Roka Bioscience has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price.  The shares are expected to begin trading on the NASDAQ Global Market on July 17, 2014 under the ticker symbol "ROKA".  The offering is expected to close on July 22, 2014, subject to customary closing conditions.    

BofA Merrill Lynch and Leerink Partners are acting as joint book-running managers for the offering. Cowen and Company and Wedbush PacGrow Life Sciences are acting as co-managers.  

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 16, 2014.  When available, copies of the final prospectus relating to this offering may be obtained from BofA Merrill Lynch, Attn: Prospectus Department, 222 Broadway, New York, NY 10038, or via email, at dg.prospectus_requests@baml.com; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, via email at syndicate@leerink.com, or by phone at (800) 808-7525, ext. 4814.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Roka Bioscience
Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our "sample-in, result-out" Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.  

Contact:
Steve Sobieski
Chief Financial Officer
(908) 605-4621
ssobieski@rokabio.com

Logo - http://photos.prnewswire.com/prnh/20140717/127927


'/>"/>
SOURCE Roka Bioscience, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
2. Sangamo BioSciences Announces Conference Call And Webcast To Discuss Global Collaboration with Biogen Idec to Develop Treatments for Hemoglobinopathies
3. Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research
4. Growth in Bioscience and Pharmaceutical R&D Drives the Market for Gene Expression Reagents, According to a New Trend Report Published by Global Industry Analysts, Inc.
5. Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
6. New 2 Hour Educational Learning Labs at MD&M West Will Feature Baxter Bioscience, BMW, Dell, GE Healthcare, Mattel, Northrup Grumman, Starbucks and Other Leading Groups in Design, Manufacturing, Engineering and Automation
7. 5W Public Relations Expands Corporate Practice, Adds PURE Bioscience, Inc. to Client Roster
8. Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
9. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
10. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
11. Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree ... products targeting the needs of consumers who are incorporating medical marijuana into their ... Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. ... to perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s ...
(Date:10/6/2017)... , ... October 06, 2017 , ... ... a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for ... Dana-Farber Cancer Institute. The event is free and open to the public, but ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):